2023
Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy
Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging-ultrasound fusionMRF-TBLow-risk diseaseSystematic biopsyLower riskRisk groupingProstate biopsyActive surveillanceHigh riskProstate cancer risk stratificationIntermediate-risk criteriaIntermediate-risk diseaseSystematic prostate biopsyCancer risk stratificationPrimary study objectiveNCCN guidelinesImage-guided approachLocalized cancerRisk stratificationBenign findingsProstate cancerClinical riskDiagnostic yieldRetrospective analysisBiopsyNCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.
Moses K, Sprenkle P, Bahler C, Box G, Carlsson S, Catalona W, Dahl D, Dall'Era M, Davis J, Drake B, Epstein J, Etzioni R, Farrington T, Garraway I, Jarrard D, Kauffman E, Kaye D, Kibel A, LaGrange C, Maroni P, Ponsky L, Reys B, Salami S, Sanchez A, Seibert T, Shaneyfelt T, Smaldone M, Sonn G, Tyson M, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi R, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 236-246. PMID: 36898362, DOI: 10.6004/jnccn.2023.0014.Peer-Reviewed Original ResearchConceptsProstate cancer early detectionNCCN guidelinesCancer early detectionEarly detectionNCCN Guidelines InsightsNegative biopsy resultsEarly Detection ProgramSignificant prostate cancerIndolent diseaseBiopsy resultsAppropriate counselingProstate cancerMultiparametric MRIDetection programRecent updatesGuidelinesTesting protocol
2022
Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.
Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.Peer-Reviewed Original ResearchConceptsGrade group 2Prostate biopsyRadical prostatectomyAdverse outcomesGroup 2GG-2Core prostate biopsyProstate cancer outcomesPatient's clinical riskClinical risk assessmentCore needle biopsyOngoing clinical needAdverse outcome predictionRetrospective reviewAdverse pathologyCAPRA scoreEntire cohortCancer outcomesPathologic diagnosisNeedle biopsyClinical riskDisease outcomeProstate cancerBiopsyDisease one